Close Menu

NEW YORK (GenomeWeb) – Proove Biosciences announced today that it has acquired Algynomics, a research-stage pain diagnostics company.

Terms of the deal were not disclosed.

Algynomics's platform and patient cohorts provide prospective data to identify individuals at increased risk for chronic pain, Proove said. Such research can be used to target pain prevention efforts, enhance patient stratification in clinical trials to identify treatment responders, produce more sensitive criteria for trial enrollment, and develop algorithms to tailor treatment for pain.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.